Dr. Heather Wakelee is an Associate Professor of Medicine at Stanford University in the Division of Oncology where she leads the thoracic medical oncology research program. She attended Princeton University as an undergraduate and Johns Hopkins University for medical school. She has authored or co-authored over 100 medical articles on lung cancer and other thoracic malignancies. Dr. Wakelee is the faculty director of the Stanford University Cancer Clinical Trials Office (CCTO). Dr. Wakelee’s focus is on clinical research in thoracic malignancies including lung cancer and thymic malignancies. Dr. Wakelee has led multiple investigator-initiated protocols and played a central role in clinical trials with bevacizumab and many other anti-angiogenic agents. She is the PI on the multinational E1505 study of adjuvant bevacizumab in NSCLC. She has also run clinical trials of drugs and drug combinations focused on overcoming EGFR and ALK inhibitor resistance, Met inhibitors and novel immune modulatory agents. Additional areas of interest include lung cancer in never-smokers, sex differences in lung cancer and novel lung cancer biomarkers. She is an active member of the Eastern Cooperative Oncology Group, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology and the International Thymic Malignancies Interest Group.